New CAR-T therapy targets tough t-cell cancers in phase 2 trial
Disease control
Recruiting now
This study tests a treatment called WU-CART-007 for people with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or not responded to other treatments. The therapy uses donor immune cells engineered to find and attack cancer cells. The goal is to se…
Phase: PHASE2 • Sponsor: Wugen, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:10 UTC